Objective(s): Effective contraceptive method use is important for HIV-positive women to meet fertility goals, prevent unintended pregnancy and reduce risk of vertical HIV transmission. Our objective was to evaluate factors associated with HIV-positive women's contraceptive method use at last coitus defined as more effective [Tier 1 and 2 methods (T1/2)] versus less effective [Tier 3 or no method (T3/none)] by the US Medical Eligibility Criteria for contraception use.
Study Design: HIV-positive women, recruited from an HIV clinic in Atlanta, Georgia, between 2013 and 2014, completed a survey of demographic, clinical and reproductive health characteristics surrounding contraception. We examined the relationship between survey responses and contraceptive method use at last coitus using χ tests and multivariate logistic regression.
Results: Thirty-one percent of this HIV-positive and predominantly African-American (90%) cohort reported usage of T1/2 methods. T1/2 methods use was higher among younger women [adjusted odds ratio (aOR)=.90, p=.008] and those in noncommitted relationships (aOR =.32, p=.027). Only 21% reported dual method use at last intercourse. Fifty-three percent and 31% reported having heard of the intrauterine device and implant, respectively. Misconceptions about contraception were common.
Conclusions: The use of T1/2 methods was more common in this cohort than in the general African-American population, but overall use and dual method use can still be improved, particularly among older women and those in noncommitted relationships.
Implications: As this population had low awareness and usage of T1/2 methods and expressed many misconceptions, reoccurring contraceptive counseling may be helpful. Providers should address patient-level barriers, pregnancy intentions, and the importance of dual method and T1/2 method use.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.contraception.2018.07.140 | DOI Listing |
Womens Health Rep (New Rochelle)
January 2025
Hospital Nuestra Señora de Fátima, Vithas Vigo, Vigo, Spain.
Objectives: This study aimed to develop an anamnesis checklist for oral contraceptive (OC) choice focused on their safety profile and associated risk factors.
Study Design: This study involved eight health care professionals in Spain, including six gynecologists and two internists, selected for their expertise in contraception counseling. We employed the design-thinking process, structured in five phases: empathizing with patients' needs, defining key areas of impact, devising innovative solutions, prototyping ideas into testable proposals, and validating prototypes.
Sex Transm Infect
January 2025
Chelsea & Westminster Hospital, London, UK.
BMJ Open
January 2025
Rheumatology, Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Mexico
Objectives: To explore the experiences and perspectives of female patients with autoimmune rheumatic diseases (ARDs) regarding sexual and reproductive health, including contraception, family planning, and pregnancy.
Design: Qualitative descriptive study using semi-structured interviews.
Setting: Specialised rheumatology clinic in a tertiary hospital in Monterrey, Mexico.
Eur J Obstet Gynecol Reprod Biol
January 2025
Département de chirurgie, centre Léon Bérard, Lyon, France; INSERM U1290 RESHAPE, France; Hôpital Femme Mère Enfant, Bron, France. Electronic address:
Unlike high-grade serous carcinoma (HGSC), which mainly affects postmenopausal women, mucinous ovarian carcinoma (MOC) affects younger patients, with a median age at diagnosis of 53 years, and is rare among premenopausal women. After they receive anticancer treatment, these women encounter specific issues involving fertility preservation (FP) and/or pregnancy, which potentially require assisted reproductive technology (ART) as well as the prescription of hormonal contraception (HC) or hormone replacement therapy (HRT). We reviewed the available literature in PubMed/Medline concerning the risks of the development of ovarian cancer (OC), including MOC, associated with ART, HC and HRT, and literature on the impact of ovarian stimulation in the context of FP and/or ART, HC and HRT in women previously treated for OC, including MOC.
View Article and Find Full Text PDFMatern Child Health J
January 2025
Department of Obstetrics and Gynecology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Objectives: In cases of preterm delivery, the Medicaid sterilization policy mandates a signed consent form at least 72 h before surgery for permanent contraception, which is less than the 30 day minimum waiting period for term births. This study evaluated the association between preterm birth and fulfillment of planned permanent contraception.
Study Design: This was a secondary analysis of a multi-center retrospective cohort study of 3013 patients with a postpartum contraceptive plan of permanent contraception.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!